Last reviewed · How we verify

artesunate-amodiaquine (AS-AQ)

Yale University · FDA-approved active Small molecule Quality 22/100

artesunate-amodiaquine (AS-AQ) is a Artemisinin derivative + aminoquinoline antimalarial combination Small molecule drug developed by Yale University. It is currently FDA-approved for Treatment of acute, uncomplicated Plasmodium falciparum malaria.

Artesunate-amodiaquine (AS-AQ), developed by Yale University, is a marketed combination therapy for the treatment of acute, uncomplicated Plasmodium falciparum malaria. Its key strength lies in the rapid parasite killing action of artesunate combined with the sustained suppression from amodiaquine, making it effective in regions where this type of malaria is prevalent. The primary risk is the presence of strong competitors such as Artemether–Lumefantrine (AL) and Dihydroartemisinin–Piperaquine (DP), both of which offer high efficacy and safety, potentially limiting AS-AQ's market share.

At a glance

Generic nameartesunate-amodiaquine (AS-AQ)
SponsorYale University
Drug classArtemisinin derivative + aminoquinoline antimalarial combination
TargetPlasmodium falciparum heme iron (Fe2+), parasite DNA, heme polymerase
ModalitySmall molecule
Therapeutic areaNeuroscience
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about artesunate-amodiaquine (AS-AQ)

What is artesunate-amodiaquine (AS-AQ)?

artesunate-amodiaquine (AS-AQ) is a Artemisinin derivative + aminoquinoline antimalarial combination drug developed by Yale University, indicated for Treatment of acute, uncomplicated Plasmodium falciparum malaria.

What is artesunate-amodiaquine (AS-AQ) used for?

artesunate-amodiaquine (AS-AQ) is indicated for Treatment of acute, uncomplicated Plasmodium falciparum malaria.

Who makes artesunate-amodiaquine (AS-AQ)?

artesunate-amodiaquine (AS-AQ) is developed and marketed by Yale University (see full Yale University pipeline at /company/yale-university).

What drug class is artesunate-amodiaquine (AS-AQ) in?

artesunate-amodiaquine (AS-AQ) belongs to the Artemisinin derivative + aminoquinoline antimalarial combination class. See all Artemisinin derivative + aminoquinoline antimalarial combination drugs at /class/artemisinin-derivative-aminoquinoline-antimalarial-combination.

What development phase is artesunate-amodiaquine (AS-AQ) in?

artesunate-amodiaquine (AS-AQ) is FDA-approved (marketed).

What does artesunate-amodiaquine (AS-AQ) target?

artesunate-amodiaquine (AS-AQ) targets Plasmodium falciparum heme iron (Fe2+), parasite DNA, heme polymerase and is a Artemisinin derivative + aminoquinoline antimalarial combination.

Related